Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK

Rhea-AI Summary

Utah Medical Products (Nasdaq: UTMD), through its wholly owned UK subsidiary Femcare, has acquired the entire ordinary share capital of Orion Medical Supplies, a UK-based niche assembler and distributor of Harm Reduction medical device kits serving the UK and European markets. Orion’s products, which aim to reduce blood-borne infections, drug-related injuries and negative social impacts, are well accepted by the UK NHS and other European organizations where Femcare and UTMD already distribute proprietary devices.

According to Utah Medical Products, the acquisition is expected to be accretive, adding about $6 million to current consolidated annual sales and benefiting from leverage of Femcare’s existing infrastructure, substantially diluting overhead as a percentage of UK sales. The purchase price was £3.6 million, funded from cash reserves, and Orion’s operations will be transitioned into Femcare’s Romsey facilities after a transition period. Additional acquisition-related risk factors will be detailed in UTMD’s Q3 2026 Form 10-Q, expected by October 15.

Positive

• Orion acquisition adds about $6 million to UTMD annual sales
• Purchase price of £3.6 million fully funded from cash reserves
• Use of Femcare infrastructure expected to dilute UK overhead percentage

Negative

• Orion operations move to Romsey requires post-acquisition transition period
• Company notes additional acquisition-related risk factors for Q3 2026 10-Q

Argus Aug 31 session

-2.25% close to close Open Argus

Details

News Market Reaction – UTMD

On Aug 31, the day this news came out, UTMD closed 2.25% below the previous close.

Data tracked by StockTitan Argus for the Aug 31 session.

Key Figures

ORION operating history: Since 2008 Annual sales contribution: About $6 million Purchase price: £3.6 million +1 more

ORION operating history

Since 2008

Private UK company

Annual sales contribution

About $6 million

Expected addition to UTMD consolidated annual sales

Purchase price

£3.6 million

Paid from cash reserves

10-Q filing deadline

October 15, 2026

Additional acquisition risk factors to be outlined

Historical Context

4 past events · Latest: Aug 04

4 events

1. Aug 04

   Quarterly dividend

   24h Move

   -0.6%

   Dividend increased 1.6%, but the stock declined 0.62% over 24 hours.

2. Jul 23

   Half-year results

   24h Move

   -7.2%

   Sales declined 12.3% year over year and management projected a full-year decline.

3. May 05

   Quarterly dividend

   24h Move

   +0.3%

   Quarterly dividend increased 1.6% versus the same quarter last year.

4. Apr 23

   First-quarter results

   24h Move

   -2.5%

   Sales and earnings declined amid lost distributor and OEM customer revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

harm reduction, ordinary share capital, accretion, 10-q

4 terms

harm reduction medical

"ORION is a niche assembler and distributor ... of Harm Reduction medical devices."

Harm reduction is a set of products, services and policies aimed at lowering the negative health and social effects of risky behaviors—such as smoking, drug use or unsafe sex—without insisting that people stop the behavior entirely. For investors, it matters because harm-reduction approaches create new markets and revenue streams, alter regulatory and legal risk, and can change consumer preferences and brand value, so companies pursuing these strategies may have different growth and risk profiles compared with those focused only on traditional products.

ordinary share capital financial

"purchased the entire ordinary share capital of Orion Medical Supplies Ltd"

Ordinary share capital is the total value of a company divided into common shares that represent ownership stakes; think of it as the number of equal “pieces of the pie” investors can buy. It matters because these shares determine who controls the company, who gets dividend payments when profits are distributed, and how much an investor’s ownership is diluted if more shares are issued, all of which affect share value and voting power.

accretion financial

"The main benefit of the acquisition is accretion in financial results."

Accretion is the gradual increase in the value of an asset or in a company’s per-share metrics that happens over time or after a transaction, such as when discounts are amortized or a deal boosts earnings per share. Investors watch accretion because it signals that their ownership or expected returns are growing rather than shrinking — like a savings account slowly earning interest or a recipe that yields a few extra servings — which can affect share price and investment decisions.

10-q regulatory

"outlined in the UTMD SEC 10-Q for the third quarter of 2026"

A 10-Q is a company’s required quarterly filing with U.S. regulators that provides updated financial statements, management discussion of results, and disclosures about risks, legal matters and operational changes. Think of it as a quarterly report card and progress update that lets investors track recent performance, spot trends or warning signs between annual reports, and make informed buy/sell decisions based on the latest verified financial and business information.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, UT / ACCESS Newswire / August 31, 2026 / Femcare Ltd. ("Femcare"), a wholly-owned subsidiary of Utah Medical Products, Inc. (Nasdaq:UTMD), announces that it has purchased the entire ordinary share capital of Orion Medical Supplies Ltd ("ORION") of the United Kingdom.

ORION is a niche assembler and distributor, primarily in the UK and Europe, of Harm Reduction medical devices. Harm Reduction refers to programs and practices that aim to minimize negative health, social and legal impacts associated with drug use, drug policies and drug laws. ORION's kits incorporate devices that are designed to reduce the spread of blood borne infections, harmful drug litter and overdose injuries and deaths, along with negative social impacts on, or caused by, drugs users.

As a private UK company since 2008, ORION developed specialized products designed to eliminate blood borne viruses and infections in a high-risk population which is not expected to decline. The former owners decided to retire.

Although the devices are not synergistic from a medical use perspective with UTMD's other devices, they are well-accepted by the NHS and by other European country organizations where Femcare and UTMD distribute other proprietary medical devices.

The main benefit of the acquisition is accretion in financial results. ORION will provide a well-established and stable revenue stream, which should add about $6 million to UTMD's current consolidated annual sales, which also have potential to expand geographically. But the main financial benefit will be taking advantage of existing Femcare infrastructure and resources, which will substantially dilute overhead expenses as a percentage of UK sales. The purchase price was £3.6 million paid from cash reserves. The ORION business operations will be moved into Femcare's existing facilities in Romsey as soon as practical after a transition period.

According to Kevin Cornwell, UTMD CEO, "This is the kind of acquisition that makes sense for UTMD: a stable, profitable and affordable business with well-accepted products, in a specialized market niche with some growth potential, where distribution to customers can be leveraged."

Investors are cautioned that actual results may differ from those projected in any of the Company's forward-looking statements. Risk factors that could cause results to differ materially from those projected in any forward-looking statements have been outlined in UTMD's public disclosure filings with the SEC. Additional risk factors associated with the acquisition of Orion Medical Supplies Ltd will be outlined in the UTMD SEC 10-Q for the third quarter of 2026 which will be filed by October 15. For more information about Femcare Ltd., please visit Femcare's website at www.femcare.co.UK. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Contact:

Brian Koopman
(801) 566-1200

SOURCE: Utah Medical Products, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Utah Medical Products (UTMD) announce about Femcare’s acquisition of Orion Medical Supplies in August 2026?

Utah Medical Products announced that its subsidiary Femcare purchased all ordinary shares of UK-based Orion Medical Supplies. According to Utah Medical Products, Orion is a niche Harm Reduction medical device assembler and distributor serving the UK and European markets.

How much revenue is Orion Medical Supplies expected to add to Utah Medical Products (UTMD)?

Orion Medical Supplies is expected to add about $6 million to UTMD’s consolidated annual sales. According to Utah Medical Products, this creates a stable revenue stream with potential for geographic expansion using existing Femcare and UTMD distribution channels.

What was the purchase price for Orion Medical Supplies in the Femcare and Utah Medical Products (UTMD) deal?

The purchase price for Orion Medical Supplies was £3.6 million, paid from cash reserves. According to Utah Medical Products, this consideration buys the entire ordinary share capital of Orion, a private UK company established in 2008.

Why does Utah Medical Products (UTMD) view the Orion Medical Supplies acquisition as financially attractive?

Utah Medical Products expects the deal to be accretive, adding about $6 million in annual sales and leveraging existing Femcare infrastructure. According to Utah Medical Products, this should substantially dilute overhead expenses as a percentage of UK sales.

How will Orion Medical Supplies be integrated into Femcare and Utah Medical Products (UTMD)?

Orion’s business operations will be moved into Femcare’s existing facilities in Romsey after a transition period. According to Utah Medical Products, the acquisition will use Femcare’s established infrastructure and resources to support Orion’s Harm Reduction product line.

What risk disclosures did Utah Medical Products (UTMD) mention regarding the Orion Medical Supplies acquisition?

Utah Medical Products cautioned that actual results may differ from forward-looking statements and referenced existing SEC risk disclosures. According to Utah Medical Products, additional acquisition-related risk factors will be outlined in its Q3 2026 Form 10-Q, expected by October 15.